Skip to content
Research Article Open access CC BY 4.0

Overview of the Advancement in the Drug Discovery and Contribution in the Drug Development Process

Estella Tembe Fokunang, Charles Ntungwen Fokunang

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 10–32 · Published 30 Nov 2022

10.9734/jamps/2022/v24i10580

Abstract

The drug discovery and development of a new chemical entity from original idea to the regulatory approval for launch into the market is a very long and complex journey. The process is complex and can take between 10-15 years, with a significant financial implication of cost of about $1 billion and more. The bioactive molecules as lead compounds may be derived from several sources such as plant, animal sources or as synthetic compounds. The odyssey of drug discovery/development may take several years elucidate valid evidence-based information from data mining, before a target selection for the progression of the drug discovery platform. The successful selection of identified drug target is an important objective for many Pharmaceutical industries before laying down a platform for research and development on hit target identification of compounds with promising biological and pharmacological activities with the potential to produce a good drug. The objective of this review paper is to develop a comprehensive review on the odyssey of drug discovery and development from the research and development standpoint with special bias within the frame of the preclinical level, hit and lead compound identification, optimization and validation, using different high throughput assay development platform. The consideration of a potential active pharmaceutical product necessitates a good test battery for hit identification, lead optimization a good process for candidate f selection of a candidate compound for drug development and putting into consideration the regulatory compliance guideline for new drug approval before the attain the market and subsequent post marketing surveillance process.

Drug discovery/development hit lead target identification new chemical entity high throughput screening assay development

References (60)

  1. 1 How to improve R&D productivity: the pharmaceutical industry's grand challenge [DOI]
  2. 2 Prevalence of Diabetes among Men and Women in China [DOI]
  3. 3 Principles of early drug discovery [DOI]
  4. 4 Discovery and development of sorafenib: a multikinase inhibitor for treating cancer [DOI]
  5. 5 How were new medicines discovered? [DOI]
  6. 6 Paul Ehrlich's magic bullet concept: 100 years of progress [DOI]
  7. 7 The Journal of Investigative Dermatology [DOI]
  8. 8 Lessons from 60 years of pharmaceutical innovation [DOI]
  9. 9 Chemical space and biology [DOI]
  10. 10 Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry [DOI]
  11. 11 Drug discovery and development: Role of basic biological research [DOI]
  12. 12 Towards the Optimal Screening Collection: A Synthesis Strategy [DOI]
  13. 13 Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval [DOI]
  14. 14 Enzyme-Catalyzed Activation of Anticancer Prodrugs [DOI]
  15. 15 Exploring biology with small organic molecules [DOI]
  16. 16 The role of the medicinal chemist in drug discovery — then and now [DOI]
  17. 17 Key cost drivers of pharmaceutical clinical trials in the United States [DOI]
  18. 18 Biophysics in drug discovery: impact, challenges and opportunities [DOI]
  19. 19 Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening [DOI]
  20. 20 3D cell culture opens new dimensions in cell-based assays [DOI]
  21. 21 Predicting druggable binding sites at the protein–protein interface [DOI]
  22. 22 Diversity-oriented synthesis; a spectrum of approaches and results [DOI]
  23. 23 Bioactivity-Guided Navigation of Chemical Space [DOI]
  24. 24 Quantifying biogenic bias in screening libraries [DOI]
  25. 25 From fragment to clinical candidate—a historical perspective [DOI]
  26. 26 The Pharmaceutical Industry and the Future of Drug Development [DOI]
  27. 27 Drug discovery: new models for industry–academic partnerships [DOI]
  28. 28 An Anniversary for Cancer Chemotherapy [DOI]
  29. 29 Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays [DOI]
  30. 30 Drug metabolism and pharmacokinetics in drug discovery.
  31. 31 Chemical Genetics: Elucidating Biological Systems with Small-Molecule Compounds [DOI]
  32. 32 The multiple roles of computational chemistry in fragment-based drug design [DOI]
  33. 33 Emerging applications of network and pathway analysis in drug discovery and development.
  34. 34 U.S. Food and Drug Administration [DOI]
  35. 35 Strategies for dealing with reactive intermediates in drug discovery and development.
  36. 36 Predicting drug-drug interactions in drug discovery: where are we now and where are we going?
  37. 37 Solid-phase synthesis and chemical space analysis of a 190-membered alkaloid/terpenoid-like library [DOI]
  38. 38 Reagent based DOS: A “Click, Click, Cyclize” strategy to probe chemical space [DOI]
  39. 39 Combinatorial chemistry: oh what a decade or two can do [DOI]
  40. 40 What drives success for specialty pharmaceuticals? [DOI]
  41. 41 The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow [DOI]
  42. 42 THE CONTRIBUTION OF SYNTHETIC ORGANIC CHEMISTRY TO ANTICANCER DRUG DEVELOPMENT [DOI]
  43. 43 The Role of Ethics in Public Health Clinical Research [DOI]
  44. 44 Drug discovery and development using chemical genomics.
  45. 45 Scalable Manufacturing of Water-Insoluble Drug Products [DOI]
  46. 46 Creating the right chemistry [DOI]
  47. 47 Beginning to manage drug discovery and development knowledge.
  48. 48 Busting the billion-dollar myth: how to slash the cost of drug development [DOI]
  49. 49 Valuation in Life Sciences: A Practical Guide [DOI]
  50. 50 Location of pharmaceutical innovation: 2000–2009 [DOI]
  51. 51 Biocatalysis in drug discovery and development [DOI]
  52. 52 Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches [DOI]
  53. 53 Molecular Docking in Formulation and Development [DOI]
  54. 54 An Overview of Methods of Extraction, Isolation and Characterization of Natural Medicinal Plant Products in Improved Traditional Medicine Research [DOI]
  55. 55 Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development [DOI]
  56. 56 Chemical Intuition in Drug Design and Discovery [DOI]
  57. 57 Pharmacovigilance of Natural Herbal Medicines Research for Efficacy, Safety and Quality Assurance of Phytomedicine Products [DOI]
  58. 58 Computational Toxicology and Drug Discovery [DOI]
  59. 59 A Planning Strategy for Diversity‐Oriented Synthesis. [DOI]
  60. 60 Drug Target Identification and Validation [DOI]

Cited by 15

The effects of patent term extension on new drug patent protection in China, Europe, and the United States

Hai-Long Zhang, Yongxia Li · Medicine in Drug Discovery · 2026

Utilizing Large Language Models and Graph Neural Networks for Protein–Protein Interaction Prediction and Isozyme Estimation

Raghad J. AbuNasser, Mostafa Z. Ali, Yaser Jararweh · 2025 2nd International Generative AI and Computational Language Modelling Conference (GACLM) · 2025

Review of Recent Medicinal Applications of Rhenium(I) Tricarbonyl Complexes

Erick Kipngetich Towett, Vuyelwa J. Tembu, Douglas Kemboi · International Journal of Molecular Sciences · 2025

Amomum subulatum: A treasure trove of anti-cancer compounds targeting TP53 protein using in vitro and in silico techniques

Sadaqat Ali, Asifa Noreen, Adeem Qamar · Frontiers in Chemistry · 2023

Physiological and genomic insights into Bacillus sp. BRTN from Baratang mud volcano with emphasis on SUF system proteins

Karuna Soren, Dibyendu Khan, Ashutosh Kabiraj · Archives of Microbiology · 2025

Overcoming Class Imbalance in Protein-Protein Interaction and Isozyme Prediction: GAN-Based Augmentation in a Transformer-GNN Framework

Raghad J. AbuNasser, Gina R. Maayah, Yaser Jararweh · 2025 3rd International Conference on Foundation and Large Language Models (FLLM) · 2025

Integrating Synthetic Accessibility Scoring and AI-Based Retrosynthesis Analysis to Evaluate AI-Generated Drug Molecules Synthesizability

Mokete Motente, Uche A. K. Chude-Okonkwo · Drugs and Drug Candidates · 2025

Showing 7 of 15 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

26

Page views

0

PDF downloads

4

Outbound clicks

15

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.